Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.

Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study

1994 • 4,980 citations

Physiology of penile erection

1995 • 1,113 citations

Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

1996 • 1,070 citations

Oral Sildenafil in the Treatment of Erectile Dysfunction

1998 • 759 citations

EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES

1998 • 595 citations

Cyclic nucleotide phosphodiesterases: Relating structure and function

2000 • 565 citations

Pharmacology of penile erection.

2001 • 521 citations

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

2000 • 399 citations

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel

2000 • 376 citations

Nitric Oxide in the Penis: Physiology and Pathology

1997 • 352 citations

Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality

2002 • 347 citations

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

2001 • 328 citations

Effects of sildenafil, a type‐5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro

1997 • 257 citations

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

2001 • 233 citations

Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase

1998 • 221 citations

Clinical Guidelines Panel on Erectile Dysfunction: Summary Report on the Treatment of Organic Erectile Dysfunction

1996 • 215 citations

On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction

2001 • 213 citations

Inhibition of Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase (Type 5) by Sildenafil and Related Compounds

1999 • 193 citations

Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

2001 • 163 citations

Definition and classification of erectile dysfunction: Report of the Nomenclature Committee of the International Society of Impotence Research

1999 • 155 citations

Identification of the cytochrome P450 enzymes involved in the N‐demethylation of sildenafil

2001 • 152 citations

Efficacy and Safety of Sildenafil Citrate for Treatment of Erectile Dysfunction in a Population With Associated Organic Risk Factors

2001 • 144 citations

Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England

2001 • 135 citations

Double–Blind, Crossover Comparison of 3 mg Apomorphine SL with Placebo and with 4 mg Apomorphine SL in Male Erectile Dysfunction

2001 • 134 citations

Guidelines on Erectile Dysfunction

2002 • 131 citations

Expression, structure and chromosomal localization of the human cGMP‐binding cGMP‐specific phosphodiesterase PDE5A gene

1998 • 113 citations

Three-year update of sildenafil citrate (Viagra) efficacy and safety.

2001 • 109 citations

CYP3A genetics in drug metabolism

2001 • 109 citations

SSI Grand Master Lecture 6 ‘The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey’

1999 • 102 citations

Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters

2002 • 95 citations

The biochemical and neurologic basis for the treatment of male erectile dysfunction.

2001 • 93 citations

Onset and duration of action of sildenafil for the treatment of erectile dysfunction

2002 • 91 citations

Allosteric sites of phosphodiesterase‐5 (PDE5)

2001 • 88 citations

Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle

2001 • 87 citations

Comparison of reported and expected deaths in sildenafil (Viagra) users

2002 • 77 citations

The prevalence and perceived aetiology of male sexual problems in a non‐clinical sample

1986 • 65 citations

A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction

2002 • 63 citations

Assessment of the efficacy and safety of Viagra® (sildenafil citrate) in men with erectile dysfunction during long-term treatment

2001 • 57 citations

Long-term efficacy and safety of oral Viagra® (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal

2000 • 53 citations

Current status of local penile therapy

2002 • 53 citations

THE ORAL EFFICACY OF VARDENAFIL HYDROCHLORIDE FOR INDUCING PENILE ERECTION IN A CONSCIOUS RABBIT MODEL

2001 • 48 citations

The influence of medication on erectile function

1997 • 42 citations

Current treatments and emerging therapeutic approaches in male erectile dysfunction

2001 • 28 citations

Sildenafil citrate (VIAGRA), an oral treatment for erectile function: 1-year, open-label, extension studies. Multicentre Study Group.

1999 • 7 citations